Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

Proposed Structure Creates Optionality for Novan

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Drug Application (NDA).